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Abstract Circulating tumor cells (CTC) are cells that have
detached from primary tumors and circulate in the blood-
stream where they are carried to other organs, leading to
seeding of new tumors and metastases. CTC have been known
to exist in the bloodstream for more than a century. With
recent progress in the area of micro- and nanotechnology, it
has been possible to adopt new approaches in CTC research.
Microscale and nanoscale studies can throw some light on the
time course of CTC appearance in blood and CTC over-
expression profiles for cancer-related markers and galvanize
the development of drugs to block metastases. CTC counts
could serve as endpoint biomarkers and as prognostic markers
for patients with a metastatic disease. This paper reviews some
of the recent researches on using micro- and nanotechnology
to capture and profile CTC.
1 Circulating tumor cells
It has been known for a long time that cells detach from
primary tumors and reach different organs through the
body’s circulating system, therefore giving them the name
“circulating tumor cells” (CTC). It was in 1869 that
Thomas Ashworth first observed circulating tumor cells in
the blood of a man with metastatic cancer using a
microscope (Ashworth 1869). He postulated that “cells
identical with those of the cancer itself being seen in the
blood may tend to throw some light upon the mode of
origin of multiple tumors existing in the same person”. A
thorough comparison of the morphology of the circulating
cells to tumor cells from different lesions led Ashworth to
conclude that “One thing is certain, that if they (CTC) came
from an existing cancer structure, they must have passed
through the greater part of the circulatory system to have
arrived at the internal saphena vein of the sound leg”. Since
the 1950s, many studies have demonstrated the presence of
CTC in blood and some of them even shed light that there
may be prognostic value on the circulating tumor cells in
patients with breast cancer (Colombo et al. 1959; Wilson
1959; Rohmsdahl et al. 1960; Soost 1960; Graeber 1961;
Rohmsdahl et al. 1961; Saito 1961; Wuest and Birk 1962;
Candar et al. 1962). Only in the 1990s did clinicians
understand the utility of CTC for diagnosis due to a study
that showed the presence of primary tumor cells lodged in
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the bone marrow before metastases become evident (Shpall
et al. 1993; Weiss and Geduldig 1991; Brugger et al. 1994;
Spall and Jones 1994). However, the capture and quantifi-
cation of such CTC in blood has faced difficult technolog-
ical hurdles because these cells are rare. CTC are no bigger
than leukocytes; their low number, typically one to ten per
milliliter makes their detection very difficult using tradi-
tional techniques such as microscopy. The shedding of CTC
into blood is a discontinuous process and the detected CTC
are often heterogenous (Paterlini-Brechot and Benali 2007;
Mocellin et al. 2006; Jacob et al. 2007). Most of the CTC
that are shed into the blood will never colonize any organs
because the vast majority of the CTC will be eliminated
from the blood circulation (Gerges et al. 2010). However,
once even a few cells manage to establish conditions for
growth at distant sites, development of tumors at those sites
seeded by the initial cells may become very efficient,
resulting in poor prognosis for the patients (Gerges et al.
2010). In carcinomas, which are solid tumors derived from
epithelial tissues, representing 80% of all diagnosed cancer
cases, CTC can often be distinguished by epithelial lineage
markers, which serve to identify CTC and ‘occult metas-
tasis’ even at the single-cell level, especially in the blood
and bone marrow of cancer patients. CTC may affect cancer
prognosis years before the onset of overt metastasis,
improve the risk assessment, and help identify patients in
need of treatment (Zieglschmid et al. 2005; Braun et al.
2005; Braun and Naume 2005). These cells themselves may
potentially provide novel therapeutic targets. To reflect
these developments, CTC detection has been introduced
into the international tumor staging systems, and their use
as tumor markers in breast cancer has been recommended
by the American Society of Clinical Oncology in 2007
(Singletary et al. 2003; Singletary and Greene 2003;
Hermanek et al. 1999).
Understanding CTC may be the first step to block
metastases and therefore could have a positive impact on
patient survival and management in the clinic. Currently,
the best data supporting the use of CTC in cancer patient
management exist for patients with primary breast cancer,
whereas other disease sites are being studied using novel
technologies. Several large studies have shown that lodging
of tumor cells in the bone marrow of patients whose
cancers tend to spread to the bone (breast, prostate) is
associated with poor prognosis (Slade and Coombes 2007).
In some cases, the detection of tumor cells in the bone
marrow had a superior prognostic value or clinical
significance compared to detection of CTC in blood (Pierga
et al. 2004). However, bone marrow biopsy is invasive and
is not suitable for repeated or routine implementation in the
clinic. CTC counts could be used to serve as prognostic
endpoint biomarkers that can be done in a minimally
invasive way by repeated blood draws. With the advent of
micro- and nanotechnology, it has become possible to
create materials, devices, and systems at the level of atoms,
molecules, and supramolecular structures. Micro- and
nanotechnology approaches are gaining momentum in
being able to capture CTC with high efficiency in blood.
2 Cancer nanotechnology and circulating tumor cells
Nanotechnology encompasses the creation, manipulation,
and utilization of materials, devices, and systems at the
level of atoms, molecules, and supramolecular structures.
Formal definitions of nanotechnology include anywhere
between 1 and 1,000 nm in size. With smaller size, new
physical properties emerge, and therefore new techniques
are required to make nanomaterials and characterize them.
Cancer-related examples of nanotechnologies include
injectable drug delivery nanovectors such as liposomes for
the therapy of breast cancer (Ferrari 2005 Mar; Park 2002);
biologically targeted, nanosized magnetic resonance
imaging (MRI) contrast agents for intraoperative imaging
in the context of neuro-oncological interventions (Kircher
et al. 2003; Neuwalt et al. 2004); and novel, nanoparticle-
based methods for high-specificity detection of DNA and
protein (Nam and Mirkin 2004). The use of micro- and
nanotechnology to detect and capture CTC in blood is a
relatively new area of research. CTC are no larger than
leukocytes and isolation of CTC from blood components is
challenging owing to their low concentration. Most of the
CTC detection systems available today use some kind of an
enrichment technique to improve detection sensitivity.
However, they also lose CTC in the process of enrichment
due to multiple batch purification steps.
The ideal detection system should be sensitive, should
have high specificity, and should be small enough to be
portable in the clinical setting. Further, the ideal CTC
detector should be able to count the number of CTC at a
rapid pace (<1 h) and should have minimum sample
preparation or purification steps. Enrichment steps should
also be avoided to minimize the loss of CTC. Finally, the
ideal CTC system should also be able to decipher biological
information such as different types of biomarkers, genetic
mutations in tumor DNA, and any other information that
reflects the biological processes occurring during metasta-
sis. Therefore, the development of an ideal CTC detector is
still far from reality. The small size of nanoparticles, ability
to create nanoparticle contrast agents, and with a suitable
detection methodology, nanotechnology can pave the way
for CTC detection and monitoring in vivo.
CTC detection methods can be classified into two types.
These are (1) immunological assays that use monoclonal
antibodies against cell surface antigens and (2) PCR-based
methods that detect tumor-specific DNA or RNA. Immu-
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nological methods have been widely used for CTC
detection. The choice of appropriate markers is a challenge
as antigens exclusively expressed by CTC and not shared by
other circulating non-tumor or blood cells are scarce.
Antibodies specific to epithelial antigens such as cytokeratin
and EpCAM are the most widely used markers for epithelial
tumor cell detection (Mostert et al. 2009). Indeed while CK19
presence in the blood has been correlated with higher levels
of metastasis and worse prognosis (Kircher et al. 2003), loss
of CK19 has also been documented in cancer cells and thus
may generate false negative results (Jacob et al. 2007). In
addition, the percentage of CK-positive cells in normal
controls ranges from 0% to 20% in instances of non-specific
binding of non-tumoral cells or in instances of specific
binding to circulating epithelial cells, which are present due
to trauma or inflammation within the body. Organ-specific
markers, including prostate-specific antigen, carcinoembryo-
genic antigen (CEA), or Her-2 have also been used.
However, false negative/positive results are also possible as
these markers are not present in all tumor cells (only up to
30% of cancer cells carry Her-2 in Her-2-positive breast
cancer) or are not entirely organ specific. More recently,
CTC detectors specific for prostate-specific membrane
antigen (PSMA) have been created to detect prostate cancer
cells with high efficiency. Several immunofluorescence-
based technologies are being used to improve the threshold
of detection (Krivacic et al. 2004; He et al. 2007).
Enrichment methods with anti-cytokeratin or combinations
of anti-cytokeratin and anti-EpCAM antibodies have been
shown to improve the enrichment process for CTC that have
low EpCAM expression (Deng et al. 2008).
3 CTC detectors
3.1 Conventional techniques
Several technologies are available for the detection of CTC
in human blood as shown in Fig. 1. Traditionally, density
gradient centrifugation is the method that has been used for
removing CTC for microscopy (Baker et al. 2003; Lara et
al. 2004; Pantel and Brakenhoff 2004). Heavier compo-
nents in the blood sink to the bottom while the lighter
mononuclear components including tumor cells float to the
top. These are then transferred to a slide and stained for
epithelial markers such as EpCAM to detect CTC. A
trained pathologist must examine the slides for CTC. This
process is time-consuming, can take days to obtain a report
for one sample, and is subject to false positives and
negatives depending on the skill of the analyst. Moreover,
density gradient centrifugation has a recovery rate no better
than 70%. The downfall of using many of these gradient
liquids is that whole blood tends to mix with the gradient if
not centrifuged immediately; therefore, total separation is
easily interrupted.
Isolation of CTC using polycarbonate filters have been
demonstrated (Pinzani et al. 2006; Vona et al. 2000, 2002,
2004; Kahn et al. 2004). It is an inexpensive and simpler
form of enrichment and capture of CTC. It exploits the fact
that CTC are significantly larger than surrounding blood
cells. The polycarbonate filters have track etching that
results in the random placement of pores. This results in
low density and often results in the fusion of two or more
pores together. Although the claimed efficiency of capture
is 50–60%, the methods are nevertheless questionable as it
is quite possible to mix CTC with leukocytes as they have
similar sizes. CTC are also not always greater than 8–
10 μm, and one can therefore produce false positive and
false negative results using this approach. One of the new
devices that is a modified form of polycarbonate filters is
the paralyne C microfilter assembly for the capture of CTC
(Zheng et al. 2007). Parylene C offers several distinctive
properties for CTC capture. It is the highest USP class IV
biocompatible polymer for implementation, and thus
biofouling is expected to be minimal for parylene C. It
has excellent mechanical properties that allow it to be
stretched up to 200% (Zheng et al. 2007). It has a high
degree of transparency in the UV and visible range, making
it possible to observe and stain CTC directly on the filter
without having to transfer cells to a glass slide. This
translates to minimal cell loss. While the use of parylene C
for CTC has shown recovery of 90%, it makes the same
assumption as the polycarbonate filter-based devices that
CTC are significantly larger than red blood cells, which is
still questionable. So, this technique suffers from the same
drawbacks as the polycarbonate filter approach, making it
prone to produce false positive or negative results.
3.2 Micrometer-scale technologies for capturing CTC
CellSearch (Veridex) is the first widespread CTC detector
that has been approved by the Food and Drug Administra-
tion (Cristofanilli et al. 2004). It works for epithelial
cancers, namely, breast, colon, and prostate. The system is
based on the enumeration of epithelial cells, which are
separated from the blood by antibody-coated magnetic
beads and identified using fluorescently labeled antibodies
against cytokeratin, and a fluorescent nuclear stain. A total
of 177 breast cancer patients were enrolled and tested for
their CTC counts over a period of 2 years. Outcomes were
assessed according to the levels of CTC at baseline, before
the patients started a new treatment for metastatic disease. It
was found that patients in a training set with levels of CTC
equal to or higher than five CTC per 7.5 ml of whole blood,
as compared to those with fewer than five CTC per 7.5 ml,
had a shorter median progression-free survival (2.7 months
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vs 7.0 months P<0.001) and shorter overall survival
(10.1 months vs 18 months P<0.001). A total of 68% of
the tumors were positive for estrogen receptor or proges-
terone receptor or both, 30% were negative for both, and
26% were positive for Her2-neu. It was found using the
multivariate Cox proportional hazards regression model
that levels of CTC at baseline and at the first follow-up visit
were the most significant predictors of progression-free and
overall survival. The study showed that, among the various
groups of patients, the level of CTC was significantly
different only in those patients who received hormone
therapy or immunotherapy or both as compared to patients
starting chemotherapy. The prognostic implications of this
study are that elevated levels of CTC in patients present
opportunities to stratify patients for investigational studies.
Systems such as CellSearch suffer from several drawbacks.
Firstly, multiple steps of batch purification and enrichment
result in CTC loss. The actual number of CTC might be
much higher to start with in each patient group. Secondly, it
might be difficult to capture cells that do not express
EpCAM, possibly because the cells have undergone
epithelial mesenchymal transformation (EMT), which
makes the cells less susceptible to stick to the antibodies
as they break free into the blood circulation. EpCAM
methods are also not useful for non-epithelial cancers such
as sarcomas. Nevertheless, this is the only FDA-approved
CTC detector currently on the market.
The CTC chip is an exciting technology that uses passive
microfluidic sorting of blood cells (Nagrath et al. 2007). The
CTC chip has 78,000 micro-posts that are etched in silicon.
Antibodies such as anti-EpCAM are functionalized on the
surfaces of the micro-posts. Anti-EpCAM provides the
specificity for CTC capture from unfractionated blood as it
is overexpressed in epithelial cells and is absent in
heamatologic cells. The CTC chip measured the number of
CTC in peripheral blood from patients with metastatic lung,
prostate, pancreatic, breast, and colon cancer in 115 of 116
samples with a range of five to 1,281 CTC per milliliter and
approximately 50% purity. The CTC chip efficiency depends
on the flow velocity of the blood because it influences the
duration of the cell–micropost contact and the shear force,
which must be sufficiently low to ensure maximum cell–
micropost attachment. The flow rates are extremely low, of
the order of 1.0 ml/h. With such a small flow rate, the CTC
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Fig. 1 Schematic of current approaches for the detection of circulating cancer cells
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chip takes 6–8 h of sorting time for one sample of 10 ml of
patient blood, followed by confocal microscopy. The yield of
the CTC capture goes to less than 20% at 3.0 ml/h (Nagrath et
al. 2007). Another drawback of the CTC chip is that it targets
only EpCAM and therefore cannot capture cells that have
undergone EMT. Finally, the CTC chip is less useful for
sarcomas which cannot be captured using EpCAM methods.
While most of the devices for CTC capture have focused
on breast cancer, highly efficient capture and enumeration
of low-abundance prostate cancer cells using prostate-
specific membrane antigen aptamers immobilized to a
polymeric microfluidic device was demonstrated recently
(Dharmasiri et al. 2009). The device consisted of 51 ultra-
high aspect ratio curvilinear channels with width similar to
prostate cell dimensions. By functionalizing the surface of
the channels with a high density of PSMA-specific
aptamers and using a flow velocity of 2.5 mm/s, the
recovery of LnCAP cells in blood spiked with 20 cells per
milliliter was found to be 90%. The total time of capture for
1 ml of sample was reported to be 29 min.
Size-selective filtration of blood to capture CTC was
described above in conventional methods of CTC capture. A
new device that was reported this year used size-selective
micro-cavity array for rapid and efficient detection of CTC
(Hasokawa et al. 2010). The size-selective microcavity array
was made of nickel electroforming. The micro-cavities were
fabricated with diameters of 8, 9, 10, and 11 μm at the top
surface. The distance between each cavity was 60 μm and a
total of 10,000 cavities were arranged in 100×100-μm
arrays. A negative pressure was introduced into the chamber
through a peristaltic pump to enable cell entrapment into the
cavities. There were ten to 100 NCI-H358 lung cancer cells
spiked into 1 ml of blood. It was reported that the device
successfully captured 97% of the lung carcinoma cells.
Further, the device was able to detect EpCAM-negative
tumor cells with an efficiency of 80%. It was found that the
maximum recovery of the cells were at 9-μm cavity size.
The technique is similar to the parylene-C-coated device
except that the pores are more optimized and the conical
shape of the pores makes it more effective to avoid clogging
of blood cells. While this is definitely an efficient device for
trapping cells, the mechanism of cell capture relying purely
on size effects is still questionable. It is possible that cancer
cells can also deform and get out of the cavities similar to red
blood cells or leukocytes. However, this method is definitely
cost-effective compared to devices that use antigen–antibody
interactions which tend to be more expensive.
3.3 Nanotechnology methods for CTC detection
Nanoscale materials can improve the scale of CTC detection in
many ways. First, nanoscale materials alter the surface
interaction of cells to the substrate. Surface topography of
nanoscale materials can lead to the adherence of cells or even
cellular differentiation. For example, it has been shown that
neuronal cells grown on silicon substrates with average surface
roughness between 20 and 100 nm promoted longevity as well
as better cell adhesion to the substrates that could be used
conveniently for recording neuronal activity in cultures (Fan et
al. 2002 Oct 15; Khan et al. 2005 Jun; Kriparamanan et al.
2006 Jul). Nanomaterials such as carbon nanotubes promote
cellular differentiation. In a recent study, 2D thin film
scaffolds composed of biocompatible polymer-grafted carbon
nanotubes (CNTs) were shown to selectively differentiate
human embryonic stem cells into neuronal cells while
maintaining excellent cell viability (Chao et al. 2009).
Fluorescence imaging showed that the neuron differentiation
efficiency of poly(acrylic acid)-grafted CNT thin films was
significantly greater than that on poly(acrylic acid) thin films.
When compared with the conventional poly-L-ornithine
surfaces, a standard substratum commonly used for neuron
culture, this new-type thin film scaffold shows enhanced
neuron differentiation. No noticeable cytotoxic effect differ-
ence was detected between these two surfaces. The surface
analysis and cell adhesion study have suggested that CNT-
based surfaces can enhance protein adsorption and cell
attachment (Chao et al. 2009). Three-dimensional nano-
structured substrates could alter the surface adhesion of the
cells and aid in the capture of CTC in blood. A recent report
showed the use of nano-pillars fabricated using top-down
manufacturing techniques that are functionalized with
EpCAM antibodies to capture CTC (Wang et al. 2009). The
three-dimensional substrates of nano-pillars are made out of
silicon. First, densely packed nanopillars of about 100–
200 nm in size were fabricated on silicon substrates using wet
chemical etching. The length of these chemically etched
nanopillars can be controlled by applying different etching
times. After the preparation of silicon nano-pillars, N-
hydroxysuccinimide functionalization chemistry is used to
introduce streptavidin onto the surfaces of the nano-pillars
substrates. Biotinylated anti-EpCAM antibodies were intro-
duced onto the streptavidin-bonded substrates for conjugation
of antibodies prior to the cell capture experiments. To test the
efficiency of cell capture of the silicon nano-pillars, a cell
suspension of an EpCAM-positive cell line, MCF7 cells, was
introduced into the silicon nanopillars and incubated for an
hour. As a control, flat silicon surfaces were used to compare
with the nano-pillar surfaces. It was found that the flat silicon
substrates only captured between 4% and 14% of the cells vs.
nano-pillars which captured 45–65% of the cells. This
suggests that 3D nano-pillars are responsible for enhanced
cell capture. It was also found that the captured cells in the
silicon nano-pillars exhibited morphological differences with
nanoscale cellular protrusions and were more elongated than
cells captured on the flat silicon surfaces. A series of artificial
CTC blood samples were prepared by spiking MCF7 cells
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into rabbit blood followed by fluorescence microscopy. It was
found that the nano-pillars were able to capture cells at
efficiencies of >40% compared to commercially available
technologies (Wang et al. 2009). While the nano-pillar
substrates offer an efficient form of cell capture, the clinical
relevance of such devices has yet to be established. More
research on why cancer cells alone attach to the nano-pillar
and elongate as opposed to leukocytes and red blood cells has
yet to be determined.
One of the most interesting nanoscale materials that are
actively researched today is carbon nanotubes for electronics,
sensing, and actuating. Most of the atoms in single-wall carbon
nanotubes are surface atoms and any change therefore in the
surface can affect their electron transport properties. The
capture of CTC using nanotubes is highly novel as it uses the
biological interactions on the surface of the nanotubes to alter
the electron transport properties of the carbon nanotube (Shao
et al. 2008). The reported device uses carbon nanotubes as
nanoscale transducing elements to capture CTC in blood.
Small bundles of carbon nanotubes were patterned between
pairs of gold electrodes. Initially, two columns composing a
ten-element array were created for looking at the interactions
of cells on nanotube surfaces that are coated with IGF1R and
Her2 antibodies. A non-specific IgG was used as an antibody
control, and MCF10A non-tumorigenic breast cells were used
as cellular controls. BT474 breast cancer cells that over-
express Her2 and MCF7 breast cancer cells that overexpress
IGF1R were spiked into blood at the level of 10,000 cells in
1 μl of human donor blood. The electrical signals were
recorded as a function of time. It was found that unique
signatures were obtained for specific and non-specific
interactions. Optical microscopy of the devices showed that,
while there may be 10,000 cells spiked in blood, only a single
cell attaches to a single device junction to create the change
in electrical signal. This was attributed to the change in
current between MCF7 cells, BT474 cells, and MCF10 A
cells. These results were reproducible and showed that the
electronic effects of semiconducting nanowire or nanotube
could in principle be used to capture CTC. Further, the device
did not foul in blood; continuous recording of electrical
signals could be obtained with ease. While the devices are
highly sensitive for capturing specific events, the clinical
utility of such devices has yet to be established for effective
capture of CTC in blood. An integrated system consisting of
arrays of sensors inside a microfluidic trap would be useful
for the capture of single CTC in blood. Further, this device
could also be useful for the profiling of receptor over-
expression in fine needle aspirates for rapid liquid biopsy.
3.4 Nanotechnology-based in vivo detection
The size, chemical and biological compatibility, and unique
physical properties of nanoscale materials can be exploited
for in vivo detection of CTC. This would definitely be a
quantum leap in technological development for monitoring
CTC, the time of release of CTC in blood, and monitoring
therapeutic efficacies. A recent report has shown the efficacy
of magnetic enrichment and photoacoustic detection of CTC
in vivo in a mice model (Galanzha et al. 2009). It takes the
approach that ex vivo methods are not sensitive enough
owing to the limited amount of blood sample volume to
monitor the onset of disease progression. Therefore, contin-
uous monitoring of blood in patients would be highly useful
to detect CTC in peripheral blood and also to monitor the
time of CTC release in blood from a primary tumor. First,
antibodies specific to a receptor in cancer cells were
conjugated to magnetic nanoparticles. These conjugated
magnetic nanoparticles captured CTC in blood, thereby
enabling invivo magnetic enrichment. A magnet was
attached to the skin of the mouse to enable enrichment of
the magnetic nanoparticles that are bound to the CTC. This
improved the photoacoustic detection from infrequent flashes
to continuous signal. To improve sensitivity, gold-plated
carbon nanotubes conjugated with folic acid were used as a
second contrast agent for photoacoustic imaging. To detect
CTC originating from the primary tumor, 5×106 MDA-MB-
231 cells were inoculated subcutaneously in mice. At 2, 3,
and 4 weeks of tumor development, a cocktail of the
conjugated nanoparticles was injected intravenously into
the circulation. Two-color photoacoustic detection of CTC at
20 min after injection showed that the ratio of the number of
CTC in mouse ear to those in abdominal vessel increased
from 0.9±0.3/6±2.1 at 2 weeks to 7.2±0.3/26±2.1 at
3 weeks and to 15.1±2.7/47±6.4 at 4 weeks. It was found
that the number of CTC that appeared roughly correlated
with the stage of primary tumor progression. This technique
of using duplex molecular targeting of CTC with iron
nanoparticles followed by their capture using dual magnet-
ic–photoacoustic flow cytometry will be highly useful
clinically, provided they are found to be tolerated in humans.
In the clinic, patients may be made to wear a magnetic jacket
for acquiring continuous photoacoustic signals as compared
to discontinuous ones. If proved successful, this in vivo
technology can be a powerful monitor as to the onset of
disease progression and therapeutic monitoring in vivo.
Further, photothermal killing of cancer cells using laser
would prove useful to eradicate cells associated with primary
tumor and block metastases.
4 Clinical relevance of CTC detectors
CTC counts could have high clinical relevance in a number
of areas in the clinical management of cancer. First, CTC
can survive chemotherapy and therefore can be a predictive
marker for the effectiveness of treatment. The Veridex study
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on 177 breast cancer patients showed that the very short
median progression-free survival in patients with elevated
levels of CTC at the first follow-up visit suggests that these
patients were receiving ineffective therapy (Vona et al.
2004). Nanotechnology methods such as nanopatterned
surfaces could potentially capture a single CTC in 10 ml of
blood, thereby enabling detection of CTC upon their release
into the blood stream. Secondly, CTC detection at low
numbers could be a prognostic marker for disease progres-
sion. Surgery or suitable therapy can be administered to
block metastases. Here again, surgery based on nanotech-
nology methods could be minimally invasive compared to
chemo- or radiotherapy. Past techniques using nano-shells
and carbon nanotubes have shown selective thermal
destruction of cancer cells using benign NIR light (Hirsch
et al. 2006 Jan; Kam et al. 2005; Panchapakesan et al.
2005; Shao et al. 2007). It is becoming more recognized
that CTC counts could indicate early versus late stage of the
disease and correlate with survival. Thirdly, the biological
aspects of CTC have still not been thoroughly delineated.
Profiling of CTC for various surface markers and quanti-
fying their degree of overexpression can provide guidance
for effective therapy. Again, nanotechnology-based
electronic, optical, and magnetic detectors could be used
to develop handheld molecular profilers that could stratify
patients in minutes based on their immunohistological
signatures. Nanotechnology-based methods can also galva-
nize customized drug cocktails to block metastases depend-
ing on the patients’ cellular profiles. Finally, the genetic
make-up of CTC is still a not well-understood phenomenon
and could throw some light into the EMT process. CTC
have recently shown to exhibit stem cell-like properties
(Marx 2007). Tumors grown using CTC in a mice model
grew twice as large in the same 3-week time period
compared to normal tumor growth from the original cell
line (Kaiser 2010). Further, CTC have also been known to
colonize their tumors of origin, in a process called “tumor
self-seeding.” Self-seeding of breast cancer, colon cancer,
and melanoma tumors in mice is preferentially mediated by
aggressive CTC, including those with bone, lung, or
brain-metastatic tropism (Kim et al. 2009). Therefore,
counting CTC before and after surgery, or therapy, profiling
CTC for their surface markers, deciphering their genetic
constituents, and administering correct and personalized
interventions in the clinic will be one of the future clinical
approaches in patient management.
5 Conclusions and future approaches
It was in 1869 that CTC were first detected, using optical
microscopy, in the blood of a patient suffering from a
metastatic disease. It has taken us more than 140 years to
recognize that CTC counts could be used as prognostic
indicators of disease progression and survival. Neverthe-
less, the recent progress in the area of micro- and
nanotechnology has led us to create many different types
of ex vivo CTC detectors with high yields (90–100%). CTC
detection in vivo is a big challenge and can sample a much
larger volume of blood compared to patient blood draws. If
in vivo methods of monitoring become successful, it can set
the stage for capturing CTC at a much earlier stage, thereby
enhancing survival. The biological aspects of CTC need to
be well delineated in order to understand the EMT process,
the timing of CTC release, and the stem cell-like properties
of CTC. These insights could galvanize the development of
future drugs to block metastases. Micro- and nanotechnol-
ogy approaches will definitely continue to impact the area
of CTC research both in vitro and in vivo. Nanoscale
devices will be more suitable in vivo due to their small size,
thereby enabling molecular targeting. Nanopatterned surfa-
ces in a micro-fluidic channel can be effective in capturing
CTC. Further, analysis of such captured CTC using
MEMS-based optical/electronic/magnetic approaches can
lead to a handheld system that will enable clinicians not
only to rapidly detect cancer cells but also to identify
immunohistochemical receptors that might enable the
stratification of patients for a specific therapy. The
simultaneous detection of CTC and selective killing of
CTC in blood vessels could result in minimally invasive
treatments for cancer that could result in longer survival
and lower cost. Batch fabrication of micro- and nanosensors
can take the level of CTC detectors down to a fraction of
the cost compared to Veridex ($600 per sample) or MRI
and CT scans (>$1,500 per scan). Micro- and nanotechnol-
ogy, if properly implemented, can lower the cost of CTC
detectors, improve sensitivity and specificity, translate the
laboratory detection of CTC to clinical settings, and
ultimately stratify patients or assess therapeutic outcomes
at a rapid pace in a clinical setting. Each of these steps is
likely to increase the overall survival of patients.
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